Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms OPTIMABI
- 18 Feb 2023 Results of the OPTIMABI trial assessing whether a dose escalation of ABI improve PFS in underexposed progressive mCRPC pts presented at the 2023 Genitourinary Cancers Symposium
- 21 Jan 2022 Status changed from active, no longer recruiting to completed.
- 15 Jan 2022 This trial has been completed in France.